BREAST FRIENDS FUND(BFF)
Over the past ten years, there has been a surge in the development of targeted agents and combination therapies. The mapping of the human and cancer genomes, and the rapid development of new technologies have revolutionized the way we understand and treat cancer. Breakthroughs in areas such as early detection and prevention, immunotherapy, epigenetics, and informatics are fueling discoveries and new treatments at an unparalleled rate. In short, the field of cancer medicine is exploding with promise.
Under the leadership of Dr. Eric Winer, Dana-Farber’s Breast Oncology Program is determined to create a future in which breast cancer is no longer a debilitating and potential lethal disease, but instead is a chronic manageable condition. The new era in breast cancer research and care is focused on deepening the understanding of the complex interactions between the molecular underpinnings of the cancer itself, the tumor’s microenvironment and the body’s immune. Inspired by their patients, Dr. Winer and his team of physician-scientists have a bold, comprehensive approach focused on tackling the most vexing problems in breast cancer. Philanthropic support is critical to the development of more effective strategies to better address treatment resistance and metastases.
Currently, Dana-Farber has several basic and translational research projects aimed at combing a variety of therapeutic agents to re-sensitize tumors to treatments, leverage the body’s immune system to eradicate all cancer cells and develop treatments to target cancer that has spread to the brain.
Your philanthropic support is vital to accelerating this work.
What is Metastatic Breast Cancer ?
Taste the Cure 2020- Postponed til May 1st
Metastatic Breast Cancer Facts*:
*Metastatic Breast Cancer Network
When breast cancer spreads to other parts of the body, such as the bones, brain, liver, or lungs, it is called metastatic (also referred to as advanced or stage IV).
Although it is not curable, metastatic breast cancer can be treatable. Today, with new therapies, including biologic targeted treatments and novel drug combinations, women with metastatic breast cancer can live well for many years.
Who is Dr. Eric Winer ?
Sandy was initially diagnosed with Stage 3 breast cancer at the age of 37, on May 30, 2013.
She chose to have a bilateral mastectomy followed by 8 rounds of chemotherapy and 28 rounds of radiation.
Soon after the end of radiation treatment Sandy was declared cancer-free.
Unfortunately, in April 2015, Sandy was no longer a breast cancer survivor. Sandy was told that the breast cancer had spread to her liver and she was now living with Stage 4 Metastatic Breast Cancer with no cure.
After being on FDA approved treatment for 3 years in July 2018 Sandy was told her cancer is growing & she needed to find a new treatment.
Sandy enrolled in a clinic trial which did not work in battling her cancer. Sandy received another FDA approved treatment beginning October 2018.
In January 2020, after a scan, Sandy once again found out her meds were not working. She worked with Dr Winer and his team, and found the next treatment. Together they put her on a newly FDA approved drug.
Please keep our family in your prayers. We will update more soon....
Dana-Farber Quick Facts:
37 Biotech companies were launched as a result of Dana-Farber research over the past 12 years
41 of the 100 new cancer drugs that gained FDA approval since 2011 were led, developed, or clinically test at
Dana-Farber/Harvard Cancer Center
Source: October 24, 2019 Presidential Visiting Committees Booklet, Fiscal Year 2018
Craig Cassanelli, Samantha Cassanelli, Amanda Cassanelli, Sandy Cassanelli and Dr. Eric Winer
from Dana-Farber Cancer Institute
Sandy on New Channel 8 discussing her runner up status for the "Remarkable Woman" Award in CT- Feb 2020
Taste the Cure 2020
updated Feb. 2020
Dr. Winer received his MD from Yale University in 1983, and later completed training in internal medicine and served as chief resident at Yale-New Haven Hospital.
He subsequently was a fellow in hematology-oncology at Duke University Medical Center, and from 1989 to 1997 served on the Duke faculty, where he became codirector of the multidisciplinary breast program.
In 1997, he joined Brigham and Women's Hospital and Dana-Farber, where he is director of the Breast Oncology Center.
Chief Clinical Strategy Officer
Chief, Division of Women's Cancers
Senior Vice President for Medical Affairs
Chief, Division of Breast Oncology Center, Susan F. Smith Center for Women's Cancers
Thompson Chair in Breast Cancer Research
Professor of Medicine, Harvard Medical School
*100 % of Funds Go To Metastatic Breast Cancer Research